Compare Logitech International SA (LOGI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Vertex Pharmaceuticals Incorporated — how do they compare? Logitech International SA trades at $98.27 (market cap $14.46B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 8.8× Logitech International SA's market cap, and Logitech International SA pays a 1.63% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Logitech International SA for 92 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| LOGI | VRTX | |
|---|---|---|
Market Cap | $14.46B | $127.55B |
Volume | 349,547 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $126.69 | $557.96 |
52-Week Low | $85.84 | $407.37 |
Typical Hold Time | 92 Days | 120 Days |
Enterprise Value | $12.79B | $121.68B |
Dividend Yield | 1.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $101.50, down 0.67% on the day, with neutral technical indicators and mixed analyst sentiment. The company demonstrates strong profitability with 45.13% gross margins and 35.29% ROE, while recent earnings beats and new product launches including Zone Vibe Pro headsets and gaming partnerships signal innovation momentum. Cash flow trends show operational strength despite recent net outflow.
Outlook remains balanced with 5.3% upside to consensus price target of $107, though analyst ratings are evenly split. Key risks include chip shortage challenges cited by management and competitive pressures in the peripheral market. Revenue growth acceleration to $4.9B projected for 2026 supports potential valuation expansion if execution continues.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, amid a bearish technical signal but strong fundamentals. The company reported $12.0B revenue and $4.0B net income for 2025, with robust profitability margins. Recent positive Phase 2b trial results for its kidney disease drug inaxaplin highlight pipeline progress. Support and resistance levels are tightly clustered around the current price, indicating potential for near-term volatility.
Outlook remains positive given dominant cystic fibrosis franchise, high margins, and promising pipeline, though earnings misses and competitive pressures pose risks. Analyst consensus is strongly bullish with a $573.50 price target, suggesting ~14% upside. Key risks include clinical trial outcomes and reliance on core franchise growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
